ATHE · Alterity Therapeutics Limited

This 6-K filing conveys a coordinated clinical communications milestone rather than a regulatory or financial event. The scheduled presentations across three high-impact neurology forums — ISMRM (imaging biomarker), MDSANZ (clinical trial results), and MSA Symposium (strategic roadmap) — collectively reinforce the maturation of Alterity’s ATH434 program in Multiple System Atrophy. Notably, the MDSANZ poster explicitly references a randomized, double-blind, placebo-controlled Phase 2 study with CSF neurofilament light (NfL) as a prespecified covariate, suggesting rigorous design and potential emphasis on disease-modifying signal. The CEO-led oral presentation at the MSA Symposium confirms active Phase 3 planning, aligning with the Company’s stated intent to initiate a pivotal trial. While no new efficacy or safety data are disclosed in this release, the timing and venue selection indicate confidence in existing datasets and readiness for late-stage development discussions with regulators and key opinion leaders. For investors, this represents de-risking through external scientific validation and increased visibility ahead of potential Phase 3 initiation — a critical inflection point for a rare, rapidly progressive disorder with no approved disease-modifying therapy.